Skip to content
<title>Channels - Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024 :: FRELIP Discovery
Channels Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024
Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025
Low level of pre-vaccination measles antibody among infants receiving measles immunization in ilorin, Kwara state, Nigeria
The use of monoclonal antibody for the immunodiagnosis of Fasciola gigantica infection in cattle
Current GMP standards for the large‐scale production of monoclonal antibodies
Development of novel monoclonal antibodies for detection of pan-Lassa virus
Development of human monoclonal antibodies against TARM1 by yeast display
Preparation and application of Taq DNA polymerase monoclonal antibody guided by structural domain analysis
Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa
Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024
Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2024-25 Respiratory Virus Season
Correction: Liquid-liquid phase separation mediated immune evasion of respiratory syncytial virus against oligoadenylate synthetase-RNase L pathway
One-for-all: a monoclonal antibody specific to different recombinant proteins in transgenic citrus plants
Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development
Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies
Assessment of miRNAs as transcriptional regulators in respiratory syncytial virus infection through computational analysis and molecular docking studies
Serological responses to killed oral cholera vaccine (OCV) when given 4 years after initial receipt of OCV in Cameroon: A randomized controlled trial
Incidence and burden of respiratory syncytial virus infection in a community-based cohort o under-five years children in Nigeria.
Improving timeliness and completion of infant vaccination among infants in Nigerian urban slums through older women's participation
Notes from the Field: Severe Medetomidine Withdrawal Syndrome in Patients Using Illegally Manufactured Opioids - Pittsburgh, Pennsylvania, October 2024-March 2025
Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025
Coverage-level and predictors of maternity continuum of care in Nigeria: implications for maternal, newborn and child health programming
